Literature DB >> 21936961

Suppressing miRNA-15a/-16 expression by interleukin-6 enhances drug-resistance in myeloma cells.

Mu Hao, Li Zhang, Gang An, Weiwei Sui, Zhen Yu, Dehui Zou, Yan Xu, Hong Chang, Lugui Qiu.   

Abstract

The bone marrow microenvironment facilitates the survival, differentiation, and proliferation of myeloma (MM) cells. This study identified that microRNA-15a and -16 expressions tightly correlated with proliferation and drug sensitivity of MM cells. miRNA-15a/-16 expression in MM cells was significantly increased after treatment with cytotoxic agents. The interaction of bone marrow stromal cells (BMSC) with MM cells resulted in decreased miRNA-15a/-16 expression and promoted the survival of the MM cells. Interleukin-6 (IL-6) produced by BMSCs suppressed the expression of miRNA-15a and 16 in a time- and dose- dependent pattern, with the suppression on miRNA-15a being more significant than on miRNA-16. miRNA-15a-transfected MM cells were found to be arrested in G1/S checkpoint, and the transfected MM cells had decreased growth and survival. In conclusion, our data suggest that via suppressing miRNA-15a and -16 expressions, IL-6 secreted by BMSCs promotes drug-resistance in myeloma cells.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21936961      PMCID: PMC3189173          DOI: 10.1186/1756-8722-4-37

Source DB:  PubMed          Journal:  J Hematol Oncol        ISSN: 1756-8722            Impact factor:   17.388


  12 in total

Review 1.  Focus on multiple myeloma.

Authors:  Constantine S Mitsiades; Nicholas Mitsiades; Nikhil C Munshi; Kenneth C Anderson
Journal:  Cancer Cell       Date:  2004-11       Impact factor: 31.743

2.  MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma.

Authors:  Aldo M Roccaro; Antonio Sacco; Brian Thompson; Xavier Leleu; Abdel Kareem Azab; Feda Azab; Judith Runnels; Xiaoying Jia; Hai T Ngo; Molly R Melhem; Charles P Lin; Domenico Ribatti; Barrett J Rollins; Thomas E Witzig; Kenneth C Anderson; Irene M Ghobrial
Journal:  Blood       Date:  2009-04-28       Impact factor: 22.113

3.  Clinical and biologic implications of recurrent genomic aberrations in myeloma.

Authors:  Rafael Fonseca; Emily Blood; Montserrat Rue; David Harrington; Martin M Oken; Robert A Kyle; Gordon W Dewald; Brian Van Ness; Scott A Van Wier; Kimberly J Henderson; Richard J Bailey; Philip R Greipp
Journal:  Blood       Date:  2003-02-06       Impact factor: 22.113

Review 4.  Applying mass spectrometry based proteomic technology to advance the understanding of multiple myeloma.

Authors:  Johann Micallef; Moyez Dharsee; Jian Chen; Suzanne Ackloo; Ken Evans; Luqui Qiu; Hong Chang
Journal:  J Hematol Oncol       Date:  2010-04-07       Impact factor: 17.388

Review 5.  Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents.

Authors:  Jiahuai Tan; Shundong Cang; Yuehua Ma; Richard L Petrillo; Delong Liu
Journal:  J Hematol Oncol       Date:  2010-02-04       Impact factor: 17.388

6.  Interleukin-6 prevents dexamethasone-induced myeloma cell death.

Authors:  J Hardin; S MacLeod; I Grigorieva; R Chang; B Barlogie; H Xiao; J Epstein
Journal:  Blood       Date:  1994-11-01       Impact factor: 22.113

7.  A phase 2 study of bortezomib in relapsed, refractory myeloma.

Authors:  Paul G Richardson; Bart Barlogie; James Berenson; Seema Singhal; Sundar Jagannath; David Irwin; S Vincent Rajkumar; Gordan Srkalovic; Melissa Alsina; Raymond Alexanian; David Siegel; Robert Z Orlowski; David Kuter; Steven A Limentani; Stephanie Lee; Teru Hideshima; Dixie-Lee Esseltine; Michael Kauffman; Julian Adams; David P Schenkein; Kenneth C Anderson
Journal:  N Engl J Med       Date:  2003-06-26       Impact factor: 91.245

Review 8.  Multiple myeloma.

Authors:  Marc S Raab; Klaus Podar; Iris Breitkreutz; Paul G Richardson; Kenneth C Anderson
Journal:  Lancet       Date:  2009-06-21       Impact factor: 79.321

Review 9.  The clinical potential of microRNAs.

Authors:  Anuradha Budhu; Junfang Ji; Xin W Wang
Journal:  J Hematol Oncol       Date:  2010-10-06       Impact factor: 17.388

Review 10.  Mechanism of action of lenalidomide in hematological malignancies.

Authors:  Venumadhav Kotla; Swati Goel; Sangeeta Nischal; Christoph Heuck; Kumar Vivek; Bhaskar Das; Amit Verma
Journal:  J Hematol Oncol       Date:  2009-08-12       Impact factor: 17.388

View more
  28 in total

1.  MiR-16 regulates crosstalk in NF-κB tolerogenic inflammatory signaling between myeloma cells and bone marrow macrophages.

Authors:  Jihane Khalife; Jayeeta Ghose; Marianna Martella; Domenico Viola; Alberto Rocci; Estelle Troadec; Cesar Terrazas; Abhay R Satoskar; Emine Gulsen Gunes; Ada Dona; James F Sanchez; P Leif Bergsagel; Marta Chesi; Alex Pozhitkov; Steven Rosen; Guido Marcucci; Jonathan J Keats; Craig C Hofmeister; Amrita Krishnan; Enrico Caserta; Flavia Pichiorri
Journal:  JCI Insight       Date:  2019-11-01

2.  miR-15a and miR-20b sensitize hepatocellular carcinoma cells to sorafenib through repressing CDC37L1 and consequent PPIA downregulation.

Authors:  Li Li; Shijun Yu; Jingde Chen; Ming Quan; Yong Gao; Yandong Li
Journal:  Cell Death Discov       Date:  2022-06-27

3.  Downregulation of miRNA-15a and miRNA-16 promote tumor proliferation in multiple myeloma by increasing CABIN1 expression.

Authors:  Lei Zhang; Lin Zhou; Meng Shi; Yong Kuang; Lei Fang
Journal:  Oncol Lett       Date:  2017-11-15       Impact factor: 2.967

Review 4.  Crosstalk between microRNA30a/b/c/d/e-5p and the canonical Wnt pathway: implications for multiple myeloma therapy.

Authors:  Jian-Jun Zhao; Ruben D Carrasco
Journal:  Cancer Res       Date:  2014-09-16       Impact factor: 12.701

5.  Low serum miR-19a expression as a novel poor prognostic indicator in multiple myeloma.

Authors:  Mu Hao; Meirong Zang; Erik Wendlandt; Yan Xu; Gang An; Dasen Gong; Fei Li; Fang Qi; Yanru Zhang; Ye Yang; Fenghuang Zhan; Lugui Qiu
Journal:  Int J Cancer       Date:  2014-09-19       Impact factor: 7.396

6.  Therapeutic effects of oligo-single-stranded DNA mimicking of hsa-miR-15a-5p on multiple myeloma.

Authors:  Zhongqing Li; Lanting Liu; Chenxing Du; Zhen Yu; Yuanyuan Yang; Jie Xu; Xiaojing Wei; Fenghuang Zhan; Yongrong Lai; Lugui Qiu; Mu Hao
Journal:  Cancer Gene Ther       Date:  2020-01-28       Impact factor: 5.987

7.  MicroRNA-15a/16-1 cluster located at chromosome 13q14 is down-regulated but displays different expression pattern and prognostic significance in multiple myeloma.

Authors:  Fei Li; Yan Xu; Shuhui Deng; Zengjun Li; Dehui Zou; Shuhua Yi; Weiwei Sui; Mu Hao; Lugui Qiu
Journal:  Oncotarget       Date:  2015-11-10

Review 8.  Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms.

Authors:  Jahangir Abdi; Guoan Chen; Hong Chang
Journal:  Oncotarget       Date:  2013-12

Review 9.  Micro-RNAs, New performers in multiple myeloma bone marrow microenvironment.

Authors:  Jahangir Abdi; Lugui Qiu; Hong Chang
Journal:  Biomark Res       Date:  2014-05-30

Review 10.  MicroRNA: important player in the pathobiology of multiple myeloma.

Authors:  Chonglei Bi; Wee Joo Chng
Journal:  Biomed Res Int       Date:  2014-06-03       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.